Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Proteomics cataloging analysis of human expressed prostatic secretions reveals rich source of biomarker candidates.

Li R, Guo Y, Han BM, Yan X, Utleg AG, Li W, Tu LC, Wang J, Hood L, Xia S, Lin B.

Proteomics Clin Appl. 2008 Apr 1;2(4):543-555.

2.

Rethinking screening for breast cancer and prostate cancer.

Esserman L, Shieh Y, Thompson I.

JAMA. 2009 Oct 21;302(15):1685-92. doi: 10.1001/jama.2009.1498.

PMID:
19843904
3.

Peptide separations by on-line MudPIT compared to isoelectric focusing in an off-gel format: application to a membrane-enriched fraction from C2C12 mouse skeletal muscle cells.

Elschenbroich S, Ignatchenko V, Sharma P, Schmitt-Ulms G, Gramolini AO, Kislinger T.

J Proteome Res. 2009 Oct;8(10):4860-9. doi: 10.1021/pr900318k.

4.

Comparative systems biology of human and mouse as a tool to guide the modeling of human placental pathology.

Cox B, Kotlyar M, Evangelou AI, Ignatchenko V, Ignatchenko A, Whiteley K, Jurisica I, Adamson SL, Rossant J, Kislinger T.

Mol Syst Biol. 2009;5:279. doi: 10.1038/msb.2009.37. Epub 2009 Jun 16.

5.

Rational approach to implementation of prostate cancer antigen 3 into clinical care.

Wang R, Chinnaiyan AM, Dunn RL, Wojno KJ, Wei JT.

Cancer. 2009 Sep 1;115(17):3879-86. doi: 10.1002/cncr.24447.

6.

Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease.

Drake RR, White KY, Fuller TW, Igwe E, Clements MA, Nyalwidhe JO, Given RW, Lance RS, Semmes OJ.

J Proteomics. 2009 Aug 20;72(6):907-17. doi: 10.1016/j.jprot.2009.01.007. Epub 2009 Jan 20. Review.

7.

The use of PCA3 in the diagnosis of prostate cancer.

Hessels D, Schalken JA.

Nat Rev Urol. 2009 May;6(5):255-61. doi: 10.1038/nrurol.2009.40. Review.

PMID:
19424173
8.

Serum proteomics using mass spectrometry.

Hood BL, Malehorn DE, Conrads TP, Bigbee WL.

Methods Mol Biol. 2009;520:107-28. doi: 10.1007/978-1-60327-811-9_8.

PMID:
19381950
9.

Automated 2D peptide separation on a 1D nano-LC-MS system.

Taylor P, Nielsen PA, Trelle MB, Hørning OB, Andersen MB, Vorm O, Moran MF, Kislinger T.

J Proteome Res. 2009 Mar;8(3):1610-6. doi: 10.1021/pr800986c.

PMID:
19178303
10.

2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer.

Byrne JC, Downes MR, O'Donoghue N, O'Keane C, O'Neill A, Fan Y, Fitzpatrick JM, Dunn M, Watson RW.

J Proteome Res. 2009 Feb;8(2):942-57. doi: 10.1021/pr800570s.

PMID:
19093873
11.

Clinical quantitation of prostate-specific antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chromatography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests.

Fortin T, Salvador A, Charrier JP, Lenz C, Lacoux X, Morla A, Choquet-Kastylevsky G, Lemoine J.

Mol Cell Proteomics. 2009 May;8(5):1006-15. doi: 10.1074/mcp.M800238-MCP200. Epub 2008 Dec 8.

12.

The Human Protein Atlas--a tool for pathology.

Pontén F, Jirström K, Uhlen M.

J Pathol. 2008 Dec;216(4):387-93. doi: 10.1002/path.2440.

PMID:
18853439
13.

Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force.

Lin K, Lipsitz R, Miller T, Janakiraman S; U.S. Preventive Services Task Force..

Ann Intern Med. 2008 Aug 5;149(3):192-9. Review.

PMID:
18678846
14.

Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers.

Sardana G, Jung K, Stephan C, Diamandis EP.

J Proteome Res. 2008 Aug;7(8):3329-38. doi: 10.1021/pr8003216. Epub 2008 Jun 26.

PMID:
18578523
15.

Identification of pathways associated with invasive behavior by ovarian cancer cells using multidimensional protein identification technology (MudPIT).

Sodek KL, Evangelou AI, Ignatchenko A, Agochiya M, Brown TJ, Ringuette MJ, Jurisica I, Kislinger T.

Mol Biosyst. 2008 Jul;4(7):762-73. doi: 10.1039/b717542f. Epub 2008 Apr 17.

PMID:
18563251
16.

Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry.

Garbis SD, Tyritzis SI, Roumeliotis T, Zerefos P, Giannopoulou EG, Vlahou A, Kossida S, Diaz J, Vourekas S, Tamvakopoulos C, Pavlakis K, Sanoudou D, Constantinides CA.

J Proteome Res. 2008 Aug;7(8):3146-58. doi: 10.1021/pr800060r. Epub 2008 Jun 14.

PMID:
18553995
17.

PCA3: a molecular urine assay for predicting prostate biopsy outcome.

Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H, Groskopf J.

J Urol. 2008 Apr;179(4):1587-92. doi: 10.1016/j.juro.2007.11.038. Epub 2008 Mar 4.

PMID:
18295257
18.

A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers.

Gortzak-Uzan L, Ignatchenko A, Evangelou AI, Agochiya M, Brown KA, St Onge P, Kireeva I, Schmitt-Ulms G, Brown TJ, Murphy J, Rosen B, Shaw P, Jurisica I, Kislinger T.

J Proteome Res. 2008 Jan;7(1):339-51. Epub 2007 Dec 13.

PMID:
18076136
19.
20.

Supplemental Content

Support Center